You are here: Welcome to the MPKB » Welcome to the MPKB » Diseases » Ankylosing spondylitis
Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
home:diseases:ankylosing_spondylitis [08.12.2019] – [Patient responses] sallieqhome:diseases:ankylosing_spondylitis [09.14.2022] (current) – external edit 127.0.0.1
Line 58: Line 58:
  
 CONCLUSION: The role of K. pneumoniae and anti-collagen antibodies in the aetiopathogenesis of CD and AS requires further study. CONCLUSION: The role of K. pneumoniae and anti-collagen antibodies in the aetiopathogenesis of CD and AS requires further study.
-(({{pubmed>long:11157137}}))</blockquote>+(({{pmid>long:11157137}}))</blockquote>
  
 [[https://ard.bmj.com/content/76/6/1123.abstract?utm_term=usage-012019&utm_content=consumer&utm_campaign=ard&utm_medium=cpc&utm_source=trendmd|Dysbiosis and zonulin upregulation alter gut epithelial and vascular barriers in patients with ankylosing spondylitis ]] [[https://ard.bmj.com/content/76/6/1123.abstract?utm_term=usage-012019&utm_content=consumer&utm_campaign=ard&utm_medium=cpc&utm_source=trendmd|Dysbiosis and zonulin upregulation alter gut epithelial and vascular barriers in patients with ankylosing spondylitis ]]
 ===== Management ===== ===== Management =====
  
-The prevalence rate of hip involvement in AS patients varies from 10 to 23%, depending on the type of hip assessment. TNF-α blocking therapy significantly improved tender hip joints, and inflammatory US lesions including positive power Doppler.   (({{pubmed>long:30624693}}))+The prevalence rate of hip involvement in AS patients varies from 10 to 23%, depending on the type of hip assessment. TNF-α blocking therapy significantly improved tender hip joints, and inflammatory US lesions including positive power Doppler.   (({{pmid>long:30624693}}))
  
  
Line 69: Line 69:
 Patients with ankylosing spondylitis (AS) warrant a comprehensive clinical assessment because of the lack of biomarkers of disease activity, prognosis and response to biologic therapy. Multiple AS-related questionnaires have been developed to assess the disease status accurately, but feasibility remains a problem in clinical practice.  Patients with ankylosing spondylitis (AS) warrant a comprehensive clinical assessment because of the lack of biomarkers of disease activity, prognosis and response to biologic therapy. Multiple AS-related questionnaires have been developed to assess the disease status accurately, but feasibility remains a problem in clinical practice. 
  
-The Bath Ankylosing Disease Activity Index remains the gold standard for assessing disease activity in a routine practice, despite poor correlation with C-reactive protein (CRP) levels and MRI inflammation.   (({{pubmed>long:30624284}}))+The Bath Ankylosing Disease Activity Index remains the gold standard for assessing disease activity in a routine practice, despite poor correlation with C-reactive protein (CRP) levels and MRI inflammation.   (({{pmid>long:30624284}}))
  
  
Line 75: Line 75:
 ==== TNF inhibitor dose ====  ==== TNF inhibitor dose ==== 
  
-In patients with ankylosing spondylitis in clinical remission for at least 6 months, dose reduction is non-inferior to full TNF inhibitor doses to maintain LDA after 1 year. Serious adverse events may be less frequent with reduced doses.   (({{pubmed>long:30621746}})) +In patients with ankylosing spondylitis in clinical remission for at least 6 months, dose reduction is non-inferior to full TNF inhibitor doses to maintain LDA after 1 year. Serious adverse events may be less frequent with reduced doses.   (({{pmid>long:30621746}})) 
  
  
Line 93: Line 93:
 ==== Related research on osteonecrosis ==== ==== Related research on osteonecrosis ====
  
-The findings from this study indicated that even short-term oral use of alendronate led to ONJ in a subset of patients after certain dental procedures were performed. These findings have important therapeutic and preventive implications.   (({{pubmed>long:19119168}}))+The findings from this study indicated that even short-term oral use of alendronate led to ONJ in a subset of patients after certain dental procedures were performed. These findings have important therapeutic and preventive implications.   (({{pmid>long:19119168}}))
  
-Oral bisphosphonate use and the prevalence of osteonecrosis of the jaw   (({{pubmed>long:30534822}}))+Oral bisphosphonate use and the prevalence of osteonecrosis of the jaw   (({{pmid>long:30534822}}))
  
    
 {{tag>diseases }} {{tag>diseases }}
  
 +<nodisp>
 ===== Notes and comments ===== ===== Notes and comments =====
  
Line 117: Line 118:
 <blockquote>Arthritis Rheum. 2009 Nov;60(11):3519-20; author reply 3520-1. <blockquote>Arthritis Rheum. 2009 Nov;60(11):3519-20; author reply 3520-1.
  
-Time to prove the infective etiology of ankylosing spondylitis and related spondylarthritides: Comment on the article by Carter et al.(({{pubmed>long:19877074}}))+Time to prove the infective etiology of ankylosing spondylitis and related spondylarthritides: Comment on the article by Carter et al.(({{pmid>long:19877074}}))
  
 Zeidler H, Rihl M. Zeidler H, Rihl M.
Line 155: Line 156:
 </blockquote> </blockquote>
  
-===== References =====+===== References =====</nodisp> 
home/diseases/ankylosing_spondylitis.1565650832.txt.gz · Last modified: by sallieq
© 2015, Autoimmunity Research Foundation. All Rights Reserved.